Aardvark Therapeutics (AARD) EBITDA (2024 - 2026)
Aardvark Therapeutics (AARD) reported EBITDA of -$22.5 million for Q1 2026, down 114.56% on a YoY basis from $154.3 million in Q1 2025, and down 20.1% sequentially from -$18.7 million in Q4 2025.
Aardvark Therapeutics (AARD) EBITDA (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of EBITDA data on file, last reported at -$22.5 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 114.56% year-over-year to -$22.5 million; the trailing twelve-month figure through Mar 2026 stood at -$74.7 million (down 140.38% YoY), and the FY2025 full-year result was -$62.7 million, down 175.29% from the prior year.
- EBITDA retreated to -$22.5 million in Q1 2026, from -$18.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.2 million in Q1 2024 to a low of -$22.5 million in Q1 2026.
- A 3-year average of -$12.0 million and a median of -$10.5 million in 2025 frame the typical range for EBITDA.
- Peak annual rise in EBITDA reached 97.93% in 2025, while the deepest fall reached 382.27% in 2025.
- Tracing AARD's EBITDA over 3 years: stood at -$9.4 million in 2024, then sank by 97.93% to -$18.7 million in 2025, then slipped by 20.1% to -$22.5 million in 2026.
- Business Quant data shows AARD's EBITDA at -$22.5 million in Q1 2026, -$18.7 million in Q4 2025, and -$17.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | -22.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.46 Mn |
| Dec 31, 2025 | -18.70 Mn |
| Sep 30, 2025 | -17.70 Mn |
| Jun 30, 2025 | -15.85 Mn |
| Mar 31, 2025 | -10.47 Mn |
| Dec 31, 2024 | -9.45 Mn |
| Sep 30, 2024 | -5.09 Mn |
| Jun 30, 2024 | -6.07 Mn |
| Mar 31, 2024 | -2.17 Mn |